Selective Growth Hormone Secretagogue
A synthetic pentapeptide GHRP that selectively stimulates GH release via GHS-R1a receptors without elevating cortisol, prolactin, or appetite — the cleanest GHRP in the research toolkit.
Research Disclaimer: This guide is for educational and research purposes only. Ipamorelin is not FDA-approved for human use. All information is based on published research and should not be construed as medical advice. It is sold for laboratory research only and is not for human or animal consumption; we do not publish dosing or stack protocols.
Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor activated by the endogenous hormone ghrelin. When Ipamorelin binds GHS-R1a on somatotroph cells in the anterior pituitary, it triggers a calcium-dependent signaling cascade that stimulates GH secretion.
What distinguishes Ipamorelin from earlier GHRPs (GHRP-6, GHRP-2) is its selectivity. Earlier GHRPs activate GHS-R1a but also engage off-target receptors that elevate cortisol, prolactin, and ACTH. Ipamorelin's structure (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) confers high selectivity for GHS-R1a with minimal off-target activity, producing a clean GH pulse without the hormonal side effects of older GHRPs.
GHRH analogues (Sermorelin, CJC-1295, Tesamorelin) act on GHRH receptors to prime the pituitary. GHRPs (Ipamorelin, GHRP-6) act on GHS-R1a receptors to trigger GH release. The two pathways are complementary: in studies of GHRH and GHRP pairs, giving both produced larger GH responses than either alone. That is why CJC-1295 and Ipamorelin are discussed together; the pairing itself has not been trialled.
GH is predominantly secreted during slow-wave sleep (SWS). Whether Ipamorelin changes sleep architecture in people has not been tested in a controlled trial; the sleep claims online are anecdotal.
Evidence: Low (GH pulse data; no sleep trials)GH axis activation via Ipamorelin promotes lipolysis and lean mass preservation. No human trial has measured a body-composition effect of Ipamorelin, alone or combined.
Evidence: Low (animal studies only)Elevated GH and downstream IGF-1 accelerate collagen synthesis, muscle protein synthesis, and tissue repair. For Ipamorelin specifically, the evidence is from animal models.
Evidence: Early-stage (preclinical + observational)Age-related decline in GH secretion (somatopause) is well-documented. Ipamorelin is studied as a means to partially restore youthful GH pulsatility. Its selective profile — without cortisol or prolactin elevation — is why it is discussed in this context; long-term human data do not exist.
Evidence: Early-stage (preclinical + observational)Understanding where Ipamorelin fits in the GH secretagogue landscape requires comparing it to both GHRH analogues (which it complements) and older GHRPs (which it largely supersedes in research protocols).
| Property | Ipamorelin | CJC-1295 | Sermorelin |
|---|---|---|---|
| Class | GHRP (ghrelin mimetic) | GHRH analogue | GHRH analogue |
| Receptor | GHS-R1a | GHRHR | GHRHR |
| Half-life | ~2 hours | ~30 min (no DAC) | ~10–20 min |
| GH release pattern | Pulsatile (selective) | Pulsatile | Pulsatile |
| Cortisol elevation | Minimal | None | None |
| Prolactin elevation | Minimal | None | None |
| Appetite stimulation | Mild | None | None |
| Synergy with GHRH | Yes — pairs with CJC-1295 | Pairs with Ipamorelin | Pairs with GHRP-2/6 |
| FDA status | Not approved | Not approved | Withdrawn 2008 |
Ipamorelin is most often discussed alongside GHRH analogues such as CJC-1295 and Sermorelin, because the two classes act on different receptors and, in studies of GHRH and GHRP pairs in general, produce larger GH responses together than apart. That is the whole of the evidence for "stacks": no trial has tested an Ipamorelin combination for sleep, body composition, recovery or ageing, and no dose or schedule has been established for any of them. The dose tables and cycles that circulate online come from forums and vendor marketing. Compound Review does not publish dosing or stack protocols; the research profile lists the published studies with citations.
Ipamorelin has one of the most favorable safety profiles among GH secretagogues, primarily because of its receptor selectivity. The absence of significant cortisol, prolactin, or ACTH elevation distinguishes it from GHRP-6 and GHRP-2.
| Effect | Frequency | Severity | Notes |
|---|---|---|---|
| Water retention | Common | Mild | Typically resolves after 2–4 weeks as the body adapts to elevated GH. |
| Injection site reactions | Common | Mild | Redness, swelling, or pain at the injection site. |
| Flushing / warmth | Common | Mild | Transient facial flushing or warmth, typically within 30 minutes of injection. Resolves spontaneously. |
| Headache | Uncommon | Mild | Reported in a subset of subjects. Possibly GH-mediated fluid shifts. Usually resolves within the first few weeks. |
| Mild appetite stimulation | Uncommon | Mild | Less pronounced than GHRP-6. Ipamorelin has partial ghrelin mimetic activity but significantly less appetite stimulation than older GHRPs. |
| Carpal tunnel symptoms | Rare | Moderate | Associated with high doses and/or prolonged use. GH-mediated fluid retention in the carpal tunnel. |
| Cortisol elevation | Minimal | Low | Ipamorelin's key advantage over GHRP-6: cortisol elevation is minimal and small in the studies that measured it. |
| Pituitary desensitization | Theoretical | Moderate | Repeated stimulation of the GH axis can blunt the response in animal studies; it has not been studied for Ipamorelin in people. |
Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist — a synthetic pentapeptide that mimics the action of ghrelin on the pituitary gland. Unlike GHRH analogues (Sermorelin, CJC-1295, Tesamorelin), Ipamorelin acts through a completely different receptor pathway (GHS-R1a) to stimulate GH release. Its key advantage is selectivity: it produces a clean GH pulse without significantly elevating cortisol, prolactin, or ACTH, which distinguishes it from older GHRPs like GHRP-6.
Ipamorelin is a GHRP (growth hormone-releasing peptide), not a GHRH analogue. It belongs to the ghrelin mimetic class and acts on GHS-R1a receptors. GHRH analogues (Sermorelin, CJC-1295, Tesamorelin) act on GHRH receptors. The two classes work through complementary pathways, which is why the two classes are often discussed together; in animal and early human studies, combining the two receptor routes produced larger GH responses than either alone.
No. Ipamorelin is not an approved drug. Its only sizeable human program, intravenous ipamorelin for bowel recovery after surgery, was a Phase 2 trial that did not meet its main goal, and no dose for any other use has been established. The '100–300 mcg two or three times a day' figures online come from forums, not trials. Compound Review does not publish dosing protocols. Ipamorelin is sold for laboratory research only and is not for human or animal consumption.
Ipamorelin is considered a second-generation GHRP with a significantly cleaner profile than GHRP-6. GHRP-6 stimulates GH release but also substantially elevates cortisol, prolactin, and ACTH, and causes significant appetite stimulation via ghrelin pathways. Ipamorelin produces selective GH release with minimal effect on cortisol, prolactin, or appetite, which is why it is the GHRP most often discussed in the research literature.
Only indirect evidence. The two act on different receptors, and studies of GHRH and GHRP pairs in general show larger GH responses together than apart. No clinical trial has tested Ipamorelin with CJC-1295 for any outcome, and the combination 'stacks' sold online are not based on one. We do not publish stack protocols.
In the human trials of intravenous ipamorelin it was generally well tolerated. Effects attributed to the GH axis in general include fluid retention, headache and flushing. Animal and early human studies found little effect on cortisol, prolactin or appetite compared with GHRP-6. The safety of long-term use of research-grade product has not been studied.
There is no research basis for a timeline. No controlled trial has measured sleep, body composition or recovery outcomes with Ipamorelin, so the week-by-week 'results' online are anecdotes.
Purgo Labs provides pharmaceutical-grade research peptides with third-party COAs. Use code HEALTH for 20% off your first order.
Shop Ipamorelin at Purgo Labs